AUTHORS
Yuky Lam, PharmD, Angela M Laza, PharmD2, Manav Patel, PharmD3, Sarah Nisly, PharmD, MEd, BCPS, FCCP4, Mandi Murph, PhD5, Krista Marcello, CHCP6, Farrukh T Awan, M.D.M.S.,M.B.A.7, Jennifer L. Crombie, MD8
AFFILIATIONS
1 Decera Clinical Education, Reston, Virginia, United States
2 Decera Clinical Education, Reston, Virginia, United States
3 Decera Clinical Education, Reston, Virginia, United States
4 Decera Clinical Education, Reston, Virginia, United States
5 Decera Clinical Education, Reston, Virginia, United States
6 Decera Clinical Education, Reston, Virginia, United States
7 University of Texas Southwestern Medical Center, Dallas, Texas, United States
8 Harvard Medical School, Boston, Massachusetts, United States
ABSTRACT
Approved bispecific antibodies (BsAb) for relapsed/refractory follicular lymphoma (R/R FL) include epcoritamab and mosunetuzumab in the United States (US), with odronextamab expanding the treatment landscape in the European Union (EU). As novel BsAbs are incorporated into the treatment of R/R FL, healthcare professionals (HCPs) require ongoing education to develop evidence-based treatment, overcome implementation barriers, and manage adverse events. To address these gaps, Decera Clinical Education developed a program: Research Focus in Relapsed/Refractory Follicular Lymphoma: Emerging Insights on Novel Bispecific Antibodies. This study evaluated pre- and post-test outcomes and polling responses across the programs on demand activities by geography (US vs non-US) and practice setting (urban vs rural) to assess knowledge, competence, and readiness to implement therapies.
Knowledge and competence were assessed using pooled test results aligned with each learning objective (LO). Two outcome questions corresponded to LO 1: overcoming barriers to integrating therapies and LO3: managing adverse events. Learning objective 2 assessed strategies for incorporating therapies. When multiple questions corresponded to 1 LO, mean percentages were calculated.
Pearson’s chi-square tests were used to compare correct responses between US and non-US learners. Fisher’s exact test was used for rural vs urban comparisons to account for small sample size. Responses were classified as correct or incorrect and stratified by geography and practice setting. The null hypothesis assumed no difference in performance between pre- and post-test results; statistical significance was set at p<0.05. Polling assessed new content, intent to change practice, and confidence in doing so.
There were over 8,800 HCPs, with 26% (n=2,265) residing outside the US. The top 3 professions were physicians (n=2,827), pharmacists (n=2,220), and nurses (n=1,125). Percentage of correct responses improved significantly among US and non-US HCPs across all LOs. For LO1, results increased by 29% (n=146) and 32% (n=123), respectively (p<0.001, for each). For LO2, results increased by 50% (n=98) and 34% (n=89), respectively (p<0.05, for each). For LO3, results increased by 19% (n=214) and 31% (n=169), respectively (p<0.05, for each).
Stratification of US learners by geographic setting revealed pre- to post-test differences. For LO1, urban HCPs demonstrated a 33% improvement (n=100; p=0.003), compared with 67% among rural HCPs (n=16; p=0.29). For LO2, rates increased by 34% among urban HCPs (n=76; p<0.05) and 50% among rural HCPs (n=14; p=0.08). For LO3, increases were similar: 29% among urban HCPs (n=176; p<0.05) and 25% among rural HCPs (n=21; p=0.21).
Polling data showed that a greater proportion of US than non-US HCPs found over 50% of the content to be new (77% vs 64%), possibly due to the earlier 2024 EU drug approval, whereas intention to change practice was lower among US HCPs (36% vs 50%). However, 64% of US HCPs reported confidence in making intended practice changes compared with 87% of non-US HCPs. Among urban vs rural HCPs, three-quarters of urban HCPs reported that at least 50% of the content was new, with 40% intending to change practice and 62% reporting confidence. Rural HCPs reported higher values, with all HCPs indicating the content was new, 50% intending to change practice, and 75% reporting confidence.
Correct-response results improved significantly across all learners, suggesting improvement in knowledge and competence. Polling suggests US HCPs were more likely to find the content new, whereas non-US HCPs reported greater confidence in changing practice, possibly reflecting earlier access to odronextamab in the EU. Differences in professional composition and subgroup size should be considered when interpreting findings. Interpretation is limited because test responses were not consistently matched at the individual level. Findings reflect aggregate improvement rather than individual learner improvement. Rural HCPs comparisons were not significant because analyses were underpowered due to the small sample of 8.
The program improved learning outcomes among all geographical and practice settings. Geographic differences in familiarity with odronextamab, may have influenced both perceived novelty and confidence in practice change. Future education should strengthen BsAb implementation among US HCPs and expand outreach to rural clinicians.
DISCLOSURES
Yuky Lam, PharmD: No relevant conflicts of interest to declare.